# | Title | Journal | Year | Citations |
---|
1 | The epidemiology of venous thromboembolism | Journal of Thrombosis and Thrombolysis | 2016 | 749 |
2 | COVID-19 update: Covid-19-associated coagulopathy | Journal of Thrombosis and Thrombolysis | 2020 | 529 |
3 | Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial | Journal of Thrombosis and Thrombolysis | 1995 | 393 |
4 | Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum | Journal of Thrombosis and Thrombolysis | 2020 | 362 |
5 | Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 | Journal of Thrombosis and Thrombolysis | 2021 | 359 |
6 | The Epidemiology of Venous Thromboembolism in the Community: Implications for Prevention and Management | Journal of Thrombosis and Thrombolysis | 2006 | 313 |
7 | Guidance for the treatment and prevention of obstetric-associated venous thromboembolism | Journal of Thrombosis and Thrombolysis | 2016 | 306 |
8 | Remodeling the Blood Coagulation Cascade | Journal of Thrombosis and Thrombolysis | 2003 | 277 |
9 | Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment | Journal of Thrombosis and Thrombolysis | 2016 | 272 |
10 | Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction | Journal of Thrombosis and Thrombolysis | 2012 | 258 |
11 | Guidance for the treatment of deep vein thrombosis and pulmonary embolism | Journal of Thrombosis and Thrombolysis | 2016 | 243 |
12 | Thrombolytic therapy in pregnancy | Journal of Thrombosis and Thrombolysis | 2006 | 240 |
13 | Incidence and cost burden of post-thrombotic syndrome | Journal of Thrombosis and Thrombolysis | 2009 | 230 |
14 | Guidance for the evaluation and treatment of hereditary and acquired thrombophilia | Journal of Thrombosis and Thrombolysis | 2016 | 230 |
15 | COVID-19-associated vasculitis and vasculopathy | Journal of Thrombosis and Thrombolysis | 2020 | 222 |
16 | Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues | Journal of Thrombosis and Thrombolysis | 2008 | 216 |
17 | COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature | Journal of Thrombosis and Thrombolysis | 2020 | 214 |
18 | Drug and dietary interactions of warfarin and novel oral anticoagulants: an update | Journal of Thrombosis and Thrombolysis | 2011 | 211 |
19 | Neutrophil extracellular traps and thrombosis in COVID-19 | Journal of Thrombosis and Thrombolysis | 2021 | 201 |
20 | Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study | Journal of Thrombosis and Thrombolysis | 2009 | 198 |
21 | Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors | Journal of Thrombosis and Thrombolysis | 2020 | 198 |
22 | Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study | Journal of Thrombosis and Thrombolysis | 2006 | 189 |
23 | Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia | Journal of Thrombosis and Thrombolysis | 2020 | 174 |
24 | Guidance for the prevention and treatment of cancer-associated venous thromboembolism | Journal of Thrombosis and Thrombolysis | 2016 | 169 |
25 | Assessing bleeding risk in patients taking anticoagulants | Journal of Thrombosis and Thrombolysis | 2013 | 165 |
26 | Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor | Journal of Thrombosis and Thrombolysis | 2011 | 163 |
27 | Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range | Journal of Thrombosis and Thrombolysis | 2003 | 159 |
28 | Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism | Journal of Thrombosis and Thrombolysis | 2016 | 156 |
29 | Thrombolysis and Counterpulsation to Improve Survival in Myocardial Infarction Complicated by Hypotension and Suspected Cardiogenic Shock or Heart Failure: Results of the TACTICS Trial | Journal of Thrombosis and Thrombolysis | 2005 | 149 |
30 | Heparin resistance in COVID-19 patients in the intensive care unit | Journal of Thrombosis and Thrombolysis | 2020 | 145 |
31 | Clinical Features of Emergency Department Patients Presenting with Symptoms Suggestive of Acute Cardiac Ischemia: A Multicenter Study | Journal of Thrombosis and Thrombolysis | 1998 | 143 |
32 | Sepsis and Disseminated Intravascular Coagulation | Journal of Thrombosis and Thrombolysis | 2003 | 143 |
33 | The association between treatment with heparin and survival in patients with Covid-19 | Journal of Thrombosis and Thrombolysis | 2020 | 140 |
34 | Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor | Journal of Thrombosis and Thrombolysis | 2011 | 136 |
35 | A guide to venous thromboembolism risk factor assessment | Journal of Thrombosis and Thrombolysis | 2000 | 134 |
36 | Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management | Journal of Thrombosis and Thrombolysis | 2000 | 133 |
37 | Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis | Journal of Thrombosis and Thrombolysis | 2020 | 133 |
38 | Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM) | Journal of Thrombosis and Thrombolysis | 2007 | 131 |
39 | Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials | Journal of Thrombosis and Thrombolysis | 2012 | 131 |
40 | Guidance for the prevention and treatment of the post-thrombotic syndrome | Journal of Thrombosis and Thrombolysis | 2016 | 131 |
41 | Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay | Journal of Thrombosis and Thrombolysis | 2011 | 129 |
42 | Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients | Journal of Thrombosis and Thrombolysis | 2020 | 127 |
43 | Current status on plasma biomarkers for acute mesenteric ischemia | Journal of Thrombosis and Thrombolysis | 2012 | 124 |
44 | Evolving Concepts in the Triad of Atherosclerosis, Inflammation and Thrombosis | Journal of Thrombosis and Thrombolysis | 2004 | 123 |
45 | Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease | Journal of Thrombosis and Thrombolysis | 1998 | 115 |
46 | Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians | Journal of Thrombosis and Thrombolysis | 2017 | 114 |
47 | Statins, inflammation and deep vein thrombosis: a systematic review | Journal of Thrombosis and Thrombolysis | 2012 | 113 |
48 | Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study | Journal of Thrombosis and Thrombolysis | 2006 | 111 |
49 | Pharmacology of anticoagulants used in the treatment of venous thromboembolism | Journal of Thrombosis and Thrombolysis | 2016 | 108 |
50 | Ischemic preconditioning may be transferable via whole blood transfusion: preliminary evidence | Journal of Thrombosis and Thrombolysis | 1999 | 106 |